独立董事候选人声明与承诺 本人林雯，已充分了解并同意由提名人 XUAN ZHAO 提名为北京键 凯科技股份有限公司第三届董事会独立董事候选人。本人公开声明， 本人具备独立董事任职资格，保证不存在任何影响本人担任北京键凯 科技股份有限公司独立董事独立性的关系，具体声明并承诺如下： （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （三）中国证监会《上市公司独立董事管理办法》和上海证券交 易所自律监管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企业兼 职（任职）问题的意见》的相关规定（如适用）； （六）中共中央纪委、教育部、监察部《关于加强高等学校反腐 倡廉建设的意见》的相关规定（如适用）； （七）中国人民银行《股份制商业银行独立董事和外部监事制度 指引》等的相关规定（如适用）； （八）中国证监会《证券基金经营机构董事、监事、高级管理人 员及从业人员监督管理办法》等的相关规定（如适用）； （九 ...

证券代码：688356 证券简称：键凯科技 公告编号：2025-024 北京键凯科技股份有限公司 关于取消监事会、修订《公司章程》及修订和制定 部分公司治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京键凯科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开 了第三届董事会第十三次会议，审议通过了《关于取消监事会并修订<公司章 程>的议案》和《关于修订和制定部分公司内部管理制度的议案》，现将具体情 况公告如下： 一、取消监事会情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券 交易所科创板股票上市规则》《上市公司章程指引》等法律、法规、规章、规 范性文件最新规定，并结合公司实际情况，公司拟取消监事会，由董事会审计 委员会行使《公司法》规定的监事会职权，《监事会议事规则》相应废止，公 司各项规章制度中涉及监事会、监事的规定不再适用，并对《公司章程》《董 事会审计委员会工作细则》等相关制度作出相应修订。 在公司股东大会审议通过取消监事会事项前，公司第三届监事会仍将严格 ...

键凯科技长期专注于医用药用聚乙二醇材料的产业化及创新应用开发。公司 基于"高纯度聚乙二醇原料研制技术"、"医用药用聚乙二醇活性衍生物研制技 术"、"聚乙二醇医药应用创新技术"等三大核心技术，借力新材料推动生物医 药创新，充分挖掘聚乙二醇材料的附加价值，持续打造更优、更快、更全的泛聚 乙二醇材料平台及技术水平先进、核心技术自主可控、产业化拓展能力强的高质 量发展整体竞争力。聚乙二醇材料方面，公司积极应对市场需求变化，持续开发 各类创新泛聚乙二醇材料，2025 年上半年共完成 44 种新结构衍生物的开发，8 种衍生物产品的工艺优化、改进与放大，86 种分析方法的开发，新完成 3 种材 料在美国食品药品监督管理局（FDA）的 DMF 备案，1 种材料在国家药品监督 管理局药品审评中心（CDE）的药用辅料登记，1 种材料在新加坡卫生科学局（HSA） 的药用辅料登记。聚乙二醇创新应用方面，2025 年上半年，公司自主研发的 3 类医疗器械注射用交联透明质酸钠凝胶项目已取得医疗器械注册证，截至本报告 披露日已获得生产许可证；注射用透明质酸钠复合溶液项目提交注册申请并获国 家药品监督管理局医疗器械技术审评中心正式受理。 未 ...

证券之星消息，8月19日化学制药板块较上一交易日下跌0.66%，上海谊众领跌。当日上证指数报收于 3727.29，下跌0.02%。深证成指报收于11821.63，下跌0.12%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603520 | 司太立 | 12.16 | 10.05% | 22.82万 | | 2.69亿 | | 603811 | 诚意药业 | 16.82 | 10.01% | 31.23万 | | 5.14亿 | | 003020 | 立方制药 | 37.00 | 9.99% | 8.94万 | | 3.23亿 | | 002940 | 昂利康 | 54.86 | 8.63% | 25.65万 | | 13.73亿 | | 300016 | 北陆药业 | 11.26 | 7.44% | 130.35万 | | 14.77亿 | | 600513 | 联环药业 | 29.47 | 6.08% | 61.98万 | | 18.12亿 | ...

Core Insights - The launch event of SILKROSE® in Beijing highlighted the innovative advancements in light medical beauty technology, featuring key industry experts and marking the introduction of the first domestically produced PEG cross-linked hyaluronic acid gel with complete independent intellectual property rights [1][8] Group 1: Product Innovation - The PEG cross-linking technology of SILKROSE® was a focal point, offering a more complex three-dimensional network structure compared to traditional products, which enhances flexibility and prevents displacement and deformation [2] - The safety design of the product is noteworthy, as the PEG fragments released after hyaluronic acid degradation can be completely metabolized in the body, eliminating accumulation risks and addressing traditional cross-linking agents' metabolic concerns [4] - Clinical data indicates that the effects of SILKROSE® can last over 9 months, achieving a balance between "natural dynamism" and "long-lasting safety" [4] Group 2: Industry Perspectives - Experts emphasized the broad application prospects of PEG cross-linking technology in the medical beauty field, with a commitment from the company to pursue technological innovation and product quality [5] - A roundtable discussion among leading medical beauty experts focused on the comprehensive evaluation system for new technologies and materials in facial rejuvenation injection treatments, highlighting a shift in the market from "incremental competition" to "quality competition" [7] Group 3: Strategic Partnerships - A strategic cooperation agreement was signed between the company and China Resources Shanghai, aiming to leverage channel advantages for accelerated market coverage of the new product [8] - Since its listing in 2020, the company has supported the development and production of various PEG-modified drugs and medical devices, both domestically and internationally [8] Group 4: Future Outlook - With the official launch of SILKROSE® and subsequent market promotion, the company aims to empower medical beauty institutions through material innovation, providing safer and higher-quality options for consumers [10]

Core Viewpoint - The launch of SILKROSE's new product marks a significant milestone in the medical aesthetics industry, showcasing innovative light medical beauty technology and the first domestically produced PEG cross-linked sodium hyaluronate gel with complete independent intellectual property rights [1][8]. Group 1: Product Innovation - The PEG cross-linking technology is highlighted as a key innovation, creating a richer three-dimensional network that enhances product elasticity and prevents displacement and deformation [2][4]. - The safety design of the product is noteworthy, as the PEG fragments released after hyaluronic acid degradation can be completely metabolized in the body, eliminating accumulation risks [4]. - Clinical data indicates that the product's effect can last over 9 months, achieving a balance between "natural dynamism" and "long-lasting safety" [4]. Group 2: Expert Insights - Experts at the event emphasized the broad application prospects of PEG cross-linking technology in the medical aesthetics field, with a focus on technological innovation and product quality [5]. - A roundtable discussion among renowned medical aesthetics experts addressed the comprehensive evaluation system for new technologies and materials in facial rejuvenation treatments, indicating a shift from "incremental competition" to "quality competition" in the light medical beauty market [7]. Group 3: Strategic Partnerships - A strategic cooperation agreement was signed between JianKai Technology and China Resources Shanghai, aiming to leverage channel advantages for accelerated market coverage of the new product [8]. - Since its listing in 2020, JianKai Technology has contributed to the development and production of various PEG-modified drugs and medical devices, both domestically and internationally [8]. Group 4: Market Outlook - With the official launch of SILKROSE and subsequent market promotion, JianKai Technology aims to empower medical beauty institutions through material innovation, fostering a win-win ecosystem for enterprises, institutions, and consumers [10].

格隆汇7月30日丨键凯科技(688356.SH)在投资者互动平台表示，公司与康希诺生物子公司康希诺（上 海）生物研发有限公司合作开发的基于新型可离子化甾醇脂质（ISL）的三组分脂质纳米颗粒（ISL-3C- LNP）递送系统在安全性提高和细胞免疫应答增强方面有显著效果，并具有组分简化与专利优势，相关 研究已发表在国际权威期刊ACS Applied Materials & Interfaces上。公司下游客户中包括部分小核酸药物 的研发企业，公司基于客户需求为客户提供各类常规或定制化产品。目前公司客户均处在临床前或早期 临床阶段，尚未对公司营业收入产生重大影响。 ...

Core Insights - The report maintains a positive outlook on small molecule drug conjugates (SMDCs) and related companies, highlighting their potential in cancer treatment due to their ability to enhance efficacy while reducing toxicity [1][5][17] - The report emphasizes the clinical advantages of SMDCs, including better tumor penetration, reduced toxicity to normal cells, and easier control over synthesis and costs compared to antibody-drug conjugates (ADCs) [5][11][12] - The report identifies domestic biopharmaceutical companies, particularly Affinivax, as leaders in the SMDC space, showcasing significant advancements in innovative cancer drug development [5][12][17] Industry Overview - The pharmaceutical and biotechnology sector has shown a relative price-to-earnings (P/E) ratio of 51.14 as of July 25, 2025, which is significantly higher than its historical low of 24.38, indicating a premium valuation compared to the broader market [19] - The report notes that the healthcare sector's valuation is 279% higher than the Shanghai Composite Index, reflecting strong investor interest and confidence in the industry [19] - Recent market performance indicates a 1.90% increase in the pharmaceutical and biotechnology sector from July 21 to July 25, 2025, ranking it 16th among 27 sub-industries [26][29] Company Focus - The report suggests monitoring companies involved in the SMDC space, including Affinivax, and those collaborating with them, such as Innovent Biologics and others, which are expected to benefit from the growing interest in innovative cancer therapies [5][17][18] - Specific companies highlighted for their innovative drug development capabilities include Innovent Biologics, Shunyi Pharmaceutical, and others, which are positioned to capitalize on the advancements in SMDC technology [5][18]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Group 1 - The core viewpoint of the article highlights the active performance of the innovative drug sector, with companies like JianKai Technology seeing a rise of over 10% [1] - Abivax, a French gastrointestinal drug developer, experienced a significant surge of 586% in its stock price after announcing positive results from its Phase III trials for its core drug obefazimod targeting moderate to severe active ulcerative colitis [1] - Other companies in the sector, including Nanjing Xinbai, Lianhuan Pharmaceutical, Weichip Bio, Dize Pharmaceutical, Shutaishen, and Kailaiying, also showed upward movement in their stock prices [1]